Site icon pharmaceutical daily

Global T-Cell Lymphoma Pipeline Market Report 2021 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “T Cell Lymphoma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “T cell lymphoma – Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

T cell lymphoma Emerging Drugs Chapters

This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

T cell lymphoma Emerging Drugs

SGX-301: Soligenix

SGX301 is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.

Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.

SP-02: Solasia Pharma

SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant lymphoma, and in particular peripheral T-cell lymphoma (PTCL). Darinaparsin was granted Orphan Drug Designation in the U.S. and Europe as a treatment of PTCL and Solasia intends to seek similar status in Japan.

It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.

Major Players working on T cell lymphoma

There are approx. 100+ key companies which are developing the T cell lymphoma. The companies which have their T cell lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Soligenix.

T cell lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.

Current Scenario and Emerging Therapies:

Key Players

Key Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o2ri8e

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version